Gilead: A Bullish Update - Gilead Sciences, Inc. (NASDAQ:GILD)

January 16, 2015 7:09 PM

4 0

Introduction: Having chronicled the progress of AbbVie's (NYSE:ABBV) competition to Gilead Science's (NASDAQ:GILD) Harvoni to treat hepatitis C infection for many months, I view today's approval of AbbVie's combination regimen called Viekirax plus Exviera (Viekira Pak in the U.S.) as the end, or the begining of the end, of market worry that has left GILD shareholders with a churning stock while many other stocks advanced since GILD first approached $100/share in August last year.

Ahead of Q4 earnings to be released in early February, this article provides a concise overview of why I think the consolidation on GILD is probably over and GILD is ready to reflect Gilead's many strengths.

Also read: BAT heaps $47 bln of peer pressure on Reynolds

Read more

To category page